Session

IBD: We treat them all - but how? (Posters)

PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

IBD: We treat them all - but how? (Posters)  et al.

METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE
METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE

IBD: We treat them all - but how? (Posters)  et al.

REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN

IBD: We treat them all - but how? (Posters)  et al.

TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

IBD: We treat them all - but how? (Posters)  et al.

THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY
THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY

IBD: We treat them all - but how? (Posters)  et al.

KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY
KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY

IBD: We treat them all - but how? (Posters)  et al.

EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD
EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD

IBD: We treat them all - but how? (Posters)  et al.

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

IBD: We treat them all - but how? (Posters)  et al.

EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT
EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT

IBD: We treat them all - but how? (Posters)  et al.

DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS

IBD: We treat them all - but how? (Posters)  et al.

DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
DISTINCT EFFECT OF ANTI-TUMOR NECROSIS FACTOR-ALFA AND CONVENTIONAL THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS

REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN
REDUCED TREATMENT ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH DIABETES MELLITUS USING NEWER ANTI-DIABETIC MEDICATIONS: AN ANALYSIS FROM THE EPI-IIRN

TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
TIME TO EFFECT OF BIOLOGICS AND SMALL MOLECULES IN MODERATELY TO SEVERELY ACTIVE LUMINAL CROHN’S DISEASE – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY
KNOW NOCEBO: PREDICTING PATIENT OUTCOMES IN A 32-MONTH ADALIMUMAB BIOSIMILAR SWITCH STUDY

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT
EARLY CONCOMITANT IMMUNOMODULATOR TREATMENT PROVIDES ADDITIONAL BENEFIT IN INFLIXIMAB TREATED PEDIATRIC IBD PATIENTS DESPITE PROACTIVE DRUG MONITORING: RETROSPECTIVE ANALYSIS OF A 10-YEAR REAL-LIFE COHORT

PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE
METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE

THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY
THIOPURINE SHUNTING IN INFLAMMATORY BOWEL DISEASE PREGNANCIES INCREASES THE RISK OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY AND CAN BE MANAGED WITH SPLIT-DOSING: A PICCOLO-X STUDY

EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD
EFFECT OF MILD OR MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF OZANIMOD

Item 1 - 20 / 20
1